Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

10369	Companies
216098	Keywords
145810	Articles
114425	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023

Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants

Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 2 years ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE

published on 04/08/2024 at 23:00, 2 years ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030

Biophytis Étude Clinique BIO101 Obésité Perte Musculaire
BRIEF

published on 04/04/2024 at 23:05, 2 years 1 month ago

Biophytis annonce le succès de son Assemblée Générale du 2 avril 2024

Biophytis Biotechnologie Assemblée Générale Développement Clinique Maladies Liées À L'âge
BRIEF

published on 04/04/2024 at 23:05, 2 years 1 month ago

Biophytis Announces Unanimous Approval in General Meeting

Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE

published on 04/04/2024 at 23:00, 2 years 1 month ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30%

Shareholders Biophytis General Meeting Resolutions Approval
PRESS RELEASE

published on 04/04/2024 at 23:00, 2 years 1 month ago

RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024
Biophytis annonce l'adoption de toutes les résolutions lors de son Assemblée Générale Mixte du 2 avril 2024. Les résultats sont disponibles sur leur site. Détails sur les activités et avertissement inclus

Biophytis Développement Biotechnologie Assemblée Générale Résultats

Accesswire

Published on 05/08/2026 at 15:00, 18 minutes ago

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Published on 05/08/2026 at 14:55, 23 minutes ago

Nepra Foods Inc. to Present at the 16th Annual LD Micro Invitational
Published on 05/08/2026 at 14:30, 48 minutes ago

Unusual Machines Hosts Live Drone Ecosystem Demonstrations at XPONENTIAL 2026
Published on 05/08/2026 at 14:00, 1 hour 18 minutes ago

BlackBerry Announces Renewal of Normal Course Issuer Bid Share Buyback Program
Published on 05/08/2026 at 14:00, 1 hour 18 minutes ago

Loop Industries to Host Fourth Quarter 2025 Earnings Conference Call

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 15:08, 10 minutes ago

Siltronic AG's Annual General Meeting approves all agenda items by a clear majority
Published on 05/08/2026 at 14:16, 1 hour 2 minutes ago

Porsche sharpens focus on core business
Published on 05/08/2026 at 13:53, 1 hour 25 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/08/2026 at 13:35, 1 hour 43 minutes ago

DeFi Technologies Announces Partnership with OMFIF's Digital Monetary Institute and Confirms Participation at the Digital Money Summit 2026 in London
Published on 05/08/2026 at 13:05, 2 hours 13 minutes ago

Philadelphia Soccer 2026 Opens Media Credentialing and Fan Registration for FIFA Fan Festival™ Philadelphia

Les Echos

Published on 05/07/2026 at 19:15, 20 hours 3 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 20 hours 3 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 20 hours 12 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 20 hours 12 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 20 hours 18 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE